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Abstract
The pathogenesis of IgA nephropathy (IgAN) may be associated with the mesangial deposition of aberrantly glycosylated
IgA1. To identify mediators affected by aberrantly glycosylated IgA1 in cultured human mesangial cells (HMCs), we
generated enzymatically modified desialylated and degalactosylated (deSial/deGal) IgA1. The state of deglycosylated IgA1
was confirmed by lectin binding to Helix aspersa (HAA) and Sambucus nigra (SNA). In the cytokine array analysis, 52 proteins
were upregulated and 34 were downregulated in HMCs after stimulation with deSial/deGal IgA1. Among them, the
secretion of adiponectin was suppressed in HMCs after stimulation with deSial/deGal IgA1. HMCs expressed mRNAs for
adiponectin and its type 1 receptor, but not the type 2 receptor. Moreover, we revealed a downregulation of adiponectin
expression in the glomeruli of renal biopsy specimens from patients with IgAN compared to those with lupus nephritis. We
also demonstrated that aberrantly glycosylated IgA1 was deposited in the mesangium of patients with IgAN by dual
staining of HAA and IgA. Moreover, the urinary HAA/SNA ratio of lectin binding was significantly higher in IgAN compared
to other kidney diseases. Since adiponectin has anti-inflammatory effects, including the inhibition of adhesion molecules
and cytokines, these data suggest that the local suppression of this adipokine by aberrantly glycosylated IgA1 could be
involved in the regulation of glomerular inflammation and sclerosis in IgAN.
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Introduction
Aberrant O-glycosylation of IgA1 is one of the main
mechanisms underlying the pathogenesis of IgA nephropathy
(IgAN). Several reports have demonstrated that the aberrantly
glycosylated IgA1 with reduced galactose (Gal) and/or sialic acid
(Sial) and increased exposure of GalNAc was present in the sera
and tonsils of patients with IgAN [1,2,3,4,5]. This suggested that
desialylated and degalactosylated IgA1 (deSial/deGal IgA1)
reacted with mesangial cells, which have a central role in
mesangial proliferative glomerulonephritis, such as IgAN [6],
and that these IgA1 altered the synthesis of mediators of
inflammation which could affect cell proliferation and apoptosis
[7,8,9] and cross-talk with other cell types, including podocytes
[10].
Adiponectin, an adipocyte-derived secretory factor, promotes
insulin sensitivity, decreases inflammation and promotes cell
survival [11]. Adiponectin is released by adipocytes and targets a
multitude of different cell types. It was first considered to be
synthesized only by adipocytes; however, recent reports have
indicated that it is also produced by other cell lineages [12]. The
most prominent target cells are hepatocytes, cardiac myocytes
[12], pancreatic beta cells, glomerular mesangial cells [13], and
podocytes [14]. The two adiponectin receptors, AdipoR1 and
AdipoR2, have been cloned, and these receptors appear to
mediate many of the actions of adiponectin [15]. Adiponectin is an
approximately 30 kDa protein that circulates in plasma as
multimeric complexes at relatively high concentrations (2–
10 mg/ml). Adiponectin circulates in plasma in three forms: as a
trimer (low molecular weight), as a hexamer (trimer-dimer) of
medium molecular weight, and as a larger multimeric high-
molecular-weight (HMW) form [16,17]. In type 1 diabetic
patients, adiponectin is associated with impaired renal function
[18]. There have been reports that the urinary adiponectin level is
significantly associated with the serum adiponectin level and
proteinuria [19] and is increased by glucocorticoid therapy in
patients with IgAN [20]. However, the role of adiponectin in the
regulation of glomerular inflammation has not been fully
elucidated.
Direct in situ demonstration of aberrantly O-glycosylated IgA1
within glomerular immune deposits has recently been reported
[21]. This method enabled us to perform qualitative and
quantitative evaluation of aberrantly glycosylated IgA1 in routine
renal biopsy samples. However, the peanut lectin binding assay
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since this lectin could bind galactose itself. The binding
characteristics of several GalNAc-specific lectins were evaluated,
and lectins from Helix aspersa (HAA) and Helix pomatia bound
exclusively to IgA1 containing Gal-deficient O-linked glycans [22].
Increased binding of HAA to serum IgA1 with high specificity and
sensitivity has been reported in Caucasian patients with IgAN [3]
and also in Japanese patients with IgAN [23], thus HAA lectin is
considered to be a GalNAc-specific lectin. Therefore, we utilized
Helix aspersa (HAA) lectin for the glomerular lectin binding assay in
patients with glomerular diseases including IgAN. Moreover, both
HAA and Sambucus nigra (SNA) lectins were applied for the urinary
lectin binding assay in patients with chronic kidney diseases, and
we analyzed the association between the level of lectin binding and
clinicopathological findings in these patients.
Based on the literature described above, the aim of this study
was to identify mediators affected by aberrantly glycosylated IgA1
in cultured human mesangial cells in vitro, to investigate the
expression and significance of this mediator, adiponectin, in the
glomeruli of patients with IgAN in vivo, and to develop novel lectin
binding assays utilizing HAA lectins for the glomeruli of human
renal biopsy specimens and utilizing HAA and SNA lectins in
urine samples from patients with various chronic kidney diseases.
Results
Generation of desialylated and degalactosylated IgA1
(deSial/deGal IgA1) by enzymatic modification using
neuraminidase and b-galactosidase
To produce deSial/deGal IgA1, human IgA was treated with
neuraminidase and b-galactosidase. The efficacy of the enzymatic
treatment of neuraminidase/b3-galactosidase was confirmed by a
lectin-binding assay using HAA (Figure S1A) and SNA (Figure
S1B), which specifically bind the terminal GalNAc and sialic acid
in the hinge region of IgA1, respectively. The deSial/deGal IgA1
reacts more strongly with the HAA lectin than native IgA (OD:
deSial/deGal IgA1 0.33960.008, native IgA 0.24860.009,
P=0.017), while it reacts more weakly to the SNA lectin than
native IgA (OD: deSial/deGal IgA1 0.19160.014, native IgA
0.35560.004, P=0.008).
Adiponectin expression is downregulated and total or
high molecular weight adiponectin decreases after
stimulation with deSial/deGal IgA1 in cultured HMCs
Cultured HMC were stimulated with native IgA or deSial/
deGal IgA1 (50 mg/ml) for 48 h and then the culture supernatant
was analyzed using a biotin label-based human cytokine array to
detect the expression levels of 507 proteins (Figure 1). A total of 85
proteins were upregulated by deSial/deGal IgA1, and IL-2Rc,
angiostatin, CCR4, IL-22 BP, and thymopoietin were the five
most strongly upregulated factors in the HMCs (Table S1). A total
of 54 proteins were downregulated by deSial/deGal IgA1, and
adiponectin, sFRP-3, osteocrin, TNF RI, and MMP-24 were the
five most strongly downregulated factors in the HMCs (Table S2).
The expression of TGF-b1 was also upregulated, although the
expression levels of PDGF, TNF-a and MCP-1 were not. In both
series of arrays of HMCs, adiponectin was dramatically downreg-
ulated (Figure 1).
Because the impact of IgA1 on mesangial adiponectin
expression is unknown, we performed a further analysis of the
protein by evaluating the expression of the adiponectin protein
after stimulation with native IgA or deSial/deGal IgA1 by ELISA
(Figure 2). In HMCs, native IgA upregulated both the total and
high molecular weight (HMW) adiponectin release to the
supernatant in a dose- and time-dependent manner (Figures 2A–
C). Native IgA also increased the total and HMW adiponectin
concentrations in cell lysates in a dose-dependent manner
(Figure 2D and 2E). Neither native IgA nor deSial/deGal IgA1
induced leptin, another adipokine, in the supernatants or cell
lysates of HMCs (Figure S2).
The HMCs expressed adiponectin and AdipoR1 mRNA to a
lesser degree after stimulation with deSial/deGal IgA1 compared
to stimulation with native IgA (Figure 3A and 3B). In contrast, the
HMCs did not express AdipoR2 mRNA regardless of the form of
IgA used for stimulation.
Adiponectin expression is downregulated in the
glomeruli of patients with IgA nephropathy in
comparison to those with lupus nephritis or minor
glomerular abnormalities
We next examined the expression of adiponectin in renal biopsy
specimens of patients with minor glomerular abnormalities
(MGA), minimal change disease (MCD), lupus nephritis (LN)
and IgA nephropathy (IgAN) by immunofluorescent staining
(details in Table 1) (Figure 4). Each section was stained for aSMA
(a marker of activated mesangial cells, red) (Figure 4A–C) and
adiponectin (green) (Figure 4D–F). Strong and segmental staining
of adiponectin was observed in the glomeruli of LN patients
(Figure 4E), and some aSMA-positive cells were colocalized with
adiponectin-positive cells (yellow, overlay images, Figure 4G–I,
arrows). Double positive areas were predominant in the glomeruli
of LN patients (Figure 4H) compared to those with MGA
(Figure 4G) and IgAN (Figure 4I). Next, each section was stained
for vWF (a marker of endothelial cells, red) (Figure 4J–L) and
adiponectin (green) (Figure 4M–O). Some vWF-positive cells were
colocalized with adiponectin-positive cells (yellow, overlay images,
Figure 4P–R, arrowheads).
Figure 1. Cytokine array analysis after stimulation of cultured
human mesangial cells (HMCs) with native IgA or deSial/deGal
IgA1. The HMCs were stimulated with native (A) or deSial/deGal IgA1
(50 mg/ml) (B) for 48 h. The culture supernatants were then applied for
a protein array analysis. After incubation of samples with array
membranes for 2 h at room temperature, the spots on the membranes
were scanned and digitized. The signal intensities of the spots obtained
from two separate experiments were analyzed. (The proteins that were
up- or downregulated by approximately 2 fold are summarized in
Tables 1 and 2.) The spots shown by arrows correspond to adiponectin.
The intensity of the spots in the membrane stimulated with native IgA
was higher than that of cells stimulated with deSial/deGal IgA1 in HMC
(A, B).
doi:10.1371/journal.pone.0033965.g001
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score in IgAN patients was significantly decreased compared with
that in LN patients (Figure 5A). A significant negative correlation
was recognized between the adiponectin staining score and the
serum IgA level in IgAN patients (Figure 5B). No other clinical or
pathological parameters listed in Table 1 significantly correlated
with the glomerular adiponectin staining score. In vessels of renal
biopsy specimens, there were no significant differences between
the adiponectin expression levels among the three groups of
patients (Figure S3). Using cultured human glomerular endothelial
cells, we investigated the expression of total and HMW
adiponectin after stimulation with native or deSial/deGal IgA1
and observed downregulation of adiponectin in these cells (Figure
S4).
Colocalization of HAA lectin with IgA deposition in the
mesangium of patients with IgA nephropathy
We next performed double staining of HAA lectin and IgA in
human renal biopsy specimens in order to clarify whether the
degalactosylated IgA1 was present in the mesangium of patients
with IgA nephropathy (Figure 6). Renal biopsy specimens from
patients with MGA (Figure 6A, 6D and 6G), LN (Figure 6B, 6E
and 6H) and IgAN (Figure 6C, 6F and 6I) were stained for HAA
lectin (red) (Figure 6A–C) and IgA (green) (Figure 6D–F), and their
images were merged (yellow) (Figure 6G–I). In IgAN patients, the
IgA-positive areas in the glomeruli were colocalized with HAA
lectin-positive areas (Figure 6I). In the glomeruli of LN patients,
HAA lectin-positive areas were rarely observed and did not
colocalize with IgA deposition (Figure 6H). No IgA deposition was
observed in the glomeruli of MGA patients (Figure 6D). A
quantitative analysis demonstrated that there was a significant
increase in the relative double positive staining intensities
(Figure 6J) and areas (Figure 6K) in the glomeruli of IgAN
patients compared to those in LN or MGA patients. The HAA
and IgA double positive areas were associated with the degree of
global sclerosis of the glomeruli in IgAN patients (correlation
coefficient 0.520, P=0.041). No other pathological parameters
listed in Table 1 significantly correlated with the HAA and IgA
double positive areas.
There is an increase in the urinary HAA/SNA ratio in
patients with IgA nephropathy
To establish a diagnostic marker of IgAN, we determined the
urinary HAA/SNA ratios using HAA and SNA lectin binding
assays (Figure 7). The HAA/SNA ratio was significantly higher in
patients with IgAN compared to those with other kidney diseases
(OKD) including LN and MGA (P,0.05) (Figure 7A) (patient
profiles are shown in Table 2). Moreover, the level of HAA
binding corrected by the urinary creatinine concentration was
significantly increased in IgAN patients compared with patients
with OKD (P,0.05) (Figure 7B). A single regression analysis
revealed there was a significant positive correlation between the
urinary HAA/SNA ratio and urinary IgA in IgAN patients
(correlation coefficient 0.381, P=0.001). No other clinical
parameters listed in Table 2 significantly correlated with the
urinary HAA/SNA ratio.
Discussion
Our results demonstrated that adiponectin was synthesized and
secreted by cultured HMCs in vitro. Stimulation with deSial/deGal
IgA1 suppressed the secretion of adiponectin in HMCs compared
to those exposed to native IgA. Moreover, we revealed that there
was a downregulation of adiponectin expression in the glomeruli
Figure 2. The ELISA of total (A, C, D) and HMW (B, E) adiponectin after stimulation of HMCs with native or deSial/deGal IgA1. In
HMCs, native IgA upregulated the total (A) and high molecular weight (HMW) (B) adiponectin release to the supernatant in a dose- (A, B) and time-
dependent manner (C). Native IgA also increased the total and HMW adiponectin concentration in cell lysates in a dose-dependent manner (D, E).
HMCs were cultured with different concentrations of native or deSial/deGal IgA1 (0, 6, 12.5, 25 or 50 mg/ml) for 48 h. For the time course study, HMCs
were cultured with 25 mg/ml of native or deSial/deGal IgA1 for 0, 1, 6, 24 or 48 h. The concentrations of adiponectin were expressed as the means 6
SE. Open diamonds, native IgA; closed circles, deSial/deGal IgA1. *P=0.05 vs. medium control; #P=0.01, native IgA vs. deSial/deGal IgA1.
doi:10.1371/journal.pone.0033965.g002
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those with LN or MGA. We also demonstrated that aberrantly
glycosylated IgA1 was deposited in the glomerular mesangium of
patients with IgA nephropathy by dual staining of HAA lectin and
IgA. In addition, the urinary HAA/SNA ratio was found to be
significantly higher in IgAN patients compared to those with
OKD.
We observed that there was a downregulation of adiponectin
expression by exposure to deSial/deGal IgA1 in HMCs and in the
glomeruli of renal biopsy specimens from patients with IgAN.
Initially, adiponectin was considered to be synthesized exclusively
by adipocytes; however, recent studies have shown that it is also
expressed by other cell types including bone-forming cells [24],
endothelial cells [25], cardiomyocytes [12], bone marrow and
peripheral lymphocytes [26], and airway epithelial cells [27]. The
results of the present study provides the first evidence that
adiponectin can be synthesized and secreted by HMCs. In
addition, stimulation of HMCs with deSial/deGal IgA1 sup-
pressed the secretion of adiponectin, but not leptin, compared to
stimulation with native IgA. While it might be pointed out that the
adiponectin content of mesangial cells seems to be lower than that
of adipose tissues, the secretion by mesangial cells may be
important, since the adiponectin secreted by mesangial cells may
mediate paracrine and/or autocrine signaling pathways rather
than the long-range mechanisms regulated by adipose tissues. Two
receptors for adiponectin, AdipoR1 and Adipo2, have been
recently cloned [15]. AdipoR1 is most highly expressed in skeletal
muscle, whereas AdipoR2 is most abundantly expressed in
hepatocytes. We clarified that the AdipoR1 gene, but not the
AdipoR2 gene, was expressed in HMCs. A similar pattern of
protein expression was previously reported in isolated rat
glomeruli as determined by a Western blotting analysis [28].
Suzuki et al. demonstrated that IgA1 in the cytoplasm of IgA1-
producing cell lines derived from patients with IgAN reacted with
HAA lectin after treatment of the cells with neuraminidase,
indicating that there was a Gal deficiency. They confirmed that
the Gal-deficient IgA1 was localized to the Golgi apparatus [4].
We observed significantly more colocalization of HAA lectin with
IgA deposits in the glomerular mesangium of IgAN patients
compared to that of LN or MGA patients. The method we used
allowed us to directly visualize the in situ deposition of aberrantly
glycosylated IgA1 in the mesangial areas corresponding to IgA
deposition; in addition, this method is easily reproducible using
routine renal biopsy specimens and, importantly, is also suitable
for quantitative evaluation of the relative amounts of colocalized
HAA lectin with IgA molecules [21]. Moldoveanu et al. reported
that a HAA-IgA ELISA could be a highly specific assay for the
detection of Gal-deficiency of IgA1 O-linked glycan and may have
potential as a non-invasive diagnostic test for IgAN [3]. Our
double staining method is a novel method to distinguish IgAN
from other glomerular diseases associated with IgA deposits,
including LN. A recent report has indicated that another N-
acetylgalactosamine-specific snail lectin, Helix pomatia agglutinin,
has a comparable binding affinity for the Gal-deficient IgA1 hinge
region [29] and future studies to evaluate this lectin using our
glomerular lectin binding assay would be informative.
It has been demonstrated that there are aberrantly glycosylated
IgA1 molecules in circulating blood, tonsils and in the mesangium
of patients with IgAN [1,2,3,4,5]. In a previous study [30], we
proposed that b1,3-galactosyltransferase (b3GalT) may be an
important enzyme responsible for regulating the post-translational
carbohydrate modification of IgA in tonsillar CD19-positive B
cells in patients with IgAN, since a decrease in the expression of
the b3GalT gene was significantly correlated with renal dysfunc-
tion, the degree of proteinuria, and the severity of the renal injury
score. Aberrantly glycosylated IgA1 is composed of N-acetylga-
lactosamine (GalNAc), with or without sialic acid, and is devoid of
a galactose moiety in patients with IgAN [31]. Mass spectrometry
or lectin binding assays have been used for the detection of
aberrantly glycosylated IgA1 in previous studies [3,32]. The use of
mass spectrometry allows detection of a difference of more detailed
carbohydrate chain structures, but processing requires several
complicated steps, and it was often difficult to analyze samples
from IgAN patients with heterogeneous clinical states. The lectin
binding assay which we utilized is convenient, with a fewer steps,
and still provides specific identification and quantitation of the
binding of each lectin.
We also demonstrated that the urinary HAA/SNA binding
ratio and HAA binding was significantly increased in IgAN
Figure 3. The expression of adiponectin, AdipoR1 and AdipoR2
genes in cultured human mesangial cells (HMCs). (A) The cDNA
from human adipocytes was utilized as a positive control for
adiponectin and the cDNA from human hepatocytes was used as a
control for AdipoR1 and AdipoR2. RT-PCR for adiponectin in HMCs after
stimulation with either native or deSial/deGal IgA1 afforded cDNA
bands of the same size (256 bp) as that amplified from human
adipocyte cDNA. RT-PCR for AdipoR1 in HMCs afforded cDNA bands of
the same size (70 bp) as that amplified from human hepatocytes. The
HMCs did not express AdipoR2 mRNA. The expression of the GAPDH
gene was used as an internal standard (350 bp). (B) The densitometric
analysis of the expression of each cDNA.
doi:10.1371/journal.pone.0033965.g003
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binding ratio significantly correlated with the urinary IgA
concentration. Galla et al. reported that monomeric IgA in the
urine appeared almost exclusively in IgAN patients and patients
with OKD, while polymeric IgA predominated in normal subjects
[33]. With this in mind, the lectin binding assay using urine
samples may be more appropriate to detect aberrantly glycosylat-
ed IgA1 than that using serum samples containing predominantly
polymeric IgA. Circulating IgA may appear in the urine due to the
damaged filtration properties of the glomerular capillary wall.
However, we did not exclude the possibility that the lectin binding
assay utilized in this study may also capture IgA-containing
immune complexes.
It was previously reported that non-selective proteinuria,
including high molecular weight proteins such as immunoglobulin,
usually increases with the progression of kidney disease [33].
Matousovic et al. reported that immune complex deposits in the
mesangium cross the filtration barrier and enter the urine because
immune complex formation, including aberrantly glycosylated
IgA1, may affect the isoelectoric charge [34]. The urinary HAA/
SNA ratio may therefore provide a measurement of the
nephritogenic form of the immunoglobulin in the urine. Several
urinary biomarkers have been reported in patients with IgAN
[35,36] and recently, the urinary EGF/MCP-1 ratio was proposed
as a prognostic marker [37]. It would be of interest to examine
whether the urinary HAA/SNA ratio can be a prognostic marker
by performing a prospective study.
This study has several limitations. First, the receptors for native
or deSial/deGal IgA1 are largely unknown, so we were not able to
elucidate the receptor-mediated signaling pathways that affect
adiponectin expression in HMCs. There are several candidates
that act as the IgA1 receptor expressed on mesangial cells. Among
them, the transferrin receptor 1 (TfR1, also called CD71) has been
identified [38], and the IgA1-TfR1 interaction resulted in
mesangial cell proliferation [39]. Since the effects of the cellular
signaling of TfR1 in mesangial cells are largely unknown, an
investigation of the relationship between TfR1 and the suppression
of adiponectin may be of great interest. Second, HMCs stimulated
Table 1. The profiles of the patients included for analysis of renal biopsies.
MGA (n=9) MCD (n=8) LN (n=17) IgAN (n=19)
Mean age (years) 42.267.6 41.569.8 35.163.7 38.664.9
Gender (male/female) 4/5 3/5 2/15 8/11
d
BMI (kg/m
2) 23.361.0 24.662.1 22.560.9 22.160.8
Laboratory data
eGFR (ml/min/1.73 m
2) 83.069.1 91.0612.9 87.967.7 80.967.2
Urinary protein (g/day) 0.760.5 7.062.0
a 2.360.7
b, c 0.960.7
c, e
Hematuria (/hpf) 0.660.2 1.460.3 40.969.7
a 39.969.2
a, d
Serum IgA (mg/dl) 235.0632.5 245.5636.9 259.5624.9 295.9623.6
Plasma glucose (mg/dl) 97.664.8 125.4622.2 101.267.1 101.666.8
HbA1c (%) 5.660.3 5.560.3 5.460.2 5.160.2
Total cholesterol (mg/dl) 208.1624.8 355.8648.7
b 221.1620.7
c 183.6619.5
c, f
HDL cholesterol (mg/dl) 74.2613.0 75.867.3 51.266.3
c 61.165.7
LDL cholesterol (mg/dl) 112.4613.1 237.5643.1
b 128.4618.3
d 97.3615.7
d, f
LDL/HDL ratio 1.660.2 3.260.7
b 2.560.3 1.860.3
d
Triglycerides (mg/dl) 126.2622.0 202.0628.1 182.3620.2
b 135.0618.6
Pathological data
IgA deposition (grade) 0.160.1 0.360.1 1.460.7
a, c 2.360.1
a, c, e
Global sclerosis (%) 1.061.3 0.160.1 2.260.7 2.460.7
Mesangial proliferation (%) 0.060.0 0.060.0 6.960.8
a, c 1.560.8
b, d, e
Mesangial sclerosis (%) 0.060.0 0.060.0 0.860.2 1.060.2
a, c
Crescent formation (%) 0.060.0 0.060.0 2.160.5 1.360.5
b, d, f
Adhesion (%) 0.060.0 0.060.0 1.860.6 3.660.6
a, c
Cell infiltration (grade) 0.260.2 0.160.1 0.960.2
b, c 0.660.2
d
Tubular atrophy (grade) 0.660.2 0.560.3 1.160.2 1.560.2
b, d
Interstitial fibrosis (grade) 0.660.2 0.360.2 1.160.2
d 1.660.2
b, c
Vascular sclerosis (grade) 0.760.2 0.860.4 0.860.2 0.960.2
MGA, minor glomerular abnormalities; MCD, minimal change disease; LN, lupus nephritis; IgAN, IgA nephropathy; eGFR, estimated glomerular filtration rate; BMI, body
mass index; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein.
a: P,0.01,
b: P,0.05 vs. MGA.
c: P,0.01,
d: P,0.05 vs. MCNS.
e: P,0.01,
f: P,0.05 vs. LN.
doi:10.1371/journal.pone.0033965.t001
Adiponectin and IgA Nephropathy
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33965by enzymatically modified deSial/deGal IgA1, which we devel-
oped in vitro, may not exhibit exactly the same response as those
stimulated by abberantly glycosylated IgA1 isolated from serum of
human IgAN. Third, with regard to the serum adiponectin levels
in patients with IgAN, Iwasa et al. reported that in males, the
serum HMW adiponectin levels correlated more strongly with
arteriolosclerosis of renal biopsy specimens in patients with IgAN
than did the total adiponectin level [40]. We initially measured the
HMW adiponectin levels in the serum from a small number of
patients with IgAN and found an inverse relationship between the
serum adiponectin level and the glomerular adiponectin staining
score (data not shown). However, a large scale study will be needed
to more precisely investigate the relationship between the serum
(systemic) and glomerular (local) adiponectin levels in IgAN
patients.
In conclusion, these results indicate that aberrantly glycosylated
IgA1 downregulates adiponectin expression in HMCs in vitro and
in the glomeruli of human IgAN patients. Glomerular lectin
binding assays using HAA demonstrated the presence of
aberrantly glycosylated IgA1 in the glomeruli predominantly in
IgAN patients. The urinary HAA to SNA binding ratios may be
useful diagnostic or prognostic markers for patients with IgAN.
Given that adiponectin exerts anti-inflammatory effects, including
the inhibition of adhesion molecules, cytokine expression and
Figure 4. The expression of adiponectin, aSMA and vWF in human renal biopsies. Immunofluorescent staining of renal biopsy specimens
from patients with minor glomerular abnormalities (MGA; A, D, G, J, M and P), lupus nephritis (LN; B, E, H, K, N and Q) and IgA nephropathy (IgAN; C, F,
I, L, O and R) are shown. (Upper panels) Each section was stained for aSMA (a marker of activated mesangial cells, red) (A–C) and adiponectin (green)
(D–F). Some aSMA-positive cells were colocalized with adiponectin-positive cells (yellow) (G–I). Double positive areas were predominant in the
glomeruli of LN patients (H, arrows) as compared to IgAN patients (I, arrows). (Lower panels) Each section was stained for vWF (a marker of
endothelial cells, red) (J–L) and adiponectin (green) (M–O). Some vWF-positive cells were colocalized with adiponectin-positive cells (yellow) (P–R,
arrowheads). Double positive areas predominated in the glomeruli of MGA patients (P). Strong and segmental staining of adiponectin was recognized
in the glomeruli of LN patients (E and N). The adiponectin staining in the glomeruli of IgAN patients was weaker than that of LN and MGA patients.
Scale bars represent 100 mm.
doi:10.1371/journal.pone.0033965.g004
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adipokine by aberrantly glycosylated IgA1 could be involved in the
glomerular inflammation and sclerosis in IgAN. Further studies
regarding the mechanisms of downregulation of adiponectin and
decreased function of the adiponectin system in the glomeruli of
IgAN patients will be of particular interest.
Materials and Methods
Generation of deSial/deGal IgA1
To remove terminal sialic acid and expose the Gal residues,
99% purified IgA from human serum (Lot no. A01111502)
(Fitzgerald Industries Laboratories, Inc., Concord, MA, USA)
was incubated for 6 h at 37uC with neuraminidase (from
Streptococcus 6646 K; Seikagaku Biobusiness Corporation, Tokyo,
Japan), using 0.1 U of enzyme per mg of IgA in 0.25 M sodium
acetate buffer containing 0.1% bovine serum albumin (Sigma, St
Louis, MO, USA) at pH 6.5 as described [9]. A portion of the
neuraminidase-treated IgA was subsequently incubated for 6 h at
37uC with b-galactosidase (from Jack beans; Seikagaku Biobusi-
ness Corporation) to remove terminal Gal and to expose GalNAc
using 0.1 U of enzyme per mg of IgA in 0.05 M citrate buffer
containing 0.1% bovine serum albumin at pH 3.5 [9]. The
enzyme-treated IgA1 was then dialyzed with distilled water,
lyophilized, and dissolved in phosphate buffered saline (pH 7.4).
(Detailed methodology is described in Methods S1.)
Lectin binding assay
The lectin binding assay was performed as described previously
with some modifications [3,34,41]. The 96-well microtiter plates
(Corning Incorporated, NY, USA) were coated with goat anti-
human IgA (SouthernBiotech, Birmingham, AL, USA) at a
concentration of 1 mg/ml. The samples, including non-treated
IgA (native IgA) and neuraminidase- and galactosidase-treated
IgA, were added to each well, incubated overnight, and diluted to
achieve comparable levels of IgA (50 mg/ml) as determined using
the IgA ELISA kit (Bethyl Laboratories, Montgomery, TX, USA).
Samples were then incubated with biotinylated lectins (10 mg/ml)
from Helix aspersa (HAA) (Sigma) [3] or Sambucus nigra agglutinin
(SNA) (Vector Laboratories, Burlingame, CA, USA) [41]. Bound
lectins were measured by the addition of avidin–horseradish
peroxidase conjugate (Vector Laboratories). Then, o-phenylendia-
mine (Sigma) was added and the absorbance was measured at
490 nm by a plate reader (Bio-Rad, Hercules, CA, USA).
(Detailed methodology is described in Methods S1.)
Culture of human mesangial cells and glomerular
endothelial cells
Human mesangial cells (HMC) were purchased from Lonza
(Walkersville, MD, USA), and human glomerular microendothe-
lial cells (hGEC) were purchased from the Applied Cell Biology
Research Institute (ACBRI) (Kirkland, WA, USA). The cell
culture conditions were described previously [42,43]. To examine
the time course and dose-dependency of the native or deSial/
deGal IgA1 on adipokine expression, the cells were cultured either
with different concentrations of deSial/deGal IgA1 or native IgA
for 48 h or with 25 mg/ml of deSial/deGal IgA1 and native IgA
for different times. (Detailed methodology is described in Methods
S1.)
Human cytokine array
A biotin label-based human antibody array kit was purchased
from RayBiotech inc. (Norcross, GA, USA). HMCs or hGECs
were stimulated with native or desialylated and degalactosylated
IgA1 (deSial/deGal IgA1) (50 mg/ml) for 48 h. Then, equal
amounts of culture supernatants were applied to a protein array
for an analysis. The membranes were developed by using an
enhanced chemiluminescence-type solution, and the spots on the
membranes were scanned and digitized using the Science Lab
2005 Multi Gauge software program, Ver3.0 (FUJIFILM, Tokyo,
Japan). The signal intensities of the spots obtained from two
separate experiments were analyzed. The intensities that changed
by more than 2-fold or were decreased to less than 1/2 were
considered to be upregulated or downregulated proteins after
stimulation with deSial/deGal IgA1 compared to stimulation with
the native IgA. (Detailed methodology is described in Methods
S1.)
ELISA
An ELISA was performed for quantification of human total
adiponectin (R&D systems, Minneapolis, MN, USA), human high
molecular weight adiponectin (Fujirebio Inc., Tokyo, Japan) or
Figure 5. The adiponectin staining score in the glomeruli of renal biopsy specimens and the relationship between the adiponectin
staining score and serum IgA in patients with IgA nephropathy (IgAN). (A) The adiponectin staining score in IgAN was significantly
decreased in IgAN patients compared with that in patients with lupus nephritis (LN). Each column shown the means 6 SE. MGA, n=9; MCD, n=8; LN,
n=17; and IgAN, n=19. **P,0.01. (B) A significantly negative correlation was found between the adiponectin staining score and serum IgA in IgAN
patients (n=19) (r=20.488, P=0.034).
doi:10.1371/journal.pone.0033965.g005
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Methods S1.)
RT-PCR
Total RNA was isolated from HMCs or hGECs by using an
RNeasy Mini kit-based system (Qiagen, Valencia, CA) [30,44]. The
sequence ofthe humanprimerpairsand the originalclonesarelisted
in Table S3. The cDNA from human adipose tissues (Nippongene
Co.,LTD, Tokyo, Japan)was used asa positivecontrol for RT-PCR
of adiponectin, and the cDNA from human liver tissues (Nippon-
gene) was used as the control for RT-PCR of adiponectin receptors.
(Detailed methodology is described in Methods S1.)
Human renal biopsy specimens and collection of urine
samples
Specimens of human renal tissues were obtained by percuta-
neous renal biopsy. The profiles of the study patients are
summarized in Table 1. The diagnosis was confirmed on the
basis of clinical symptoms and immunofluorescent and light
microscopic findings. In patients with LN, 9 were categorized as
class IV, 5 as class III, 2 as class V and 1 was categorized as class
VI. Fifteen out of 17 patients with LN were receiving
corticosteroids or immunosuppressants at the time of renal
biopsy. Human spot urine was collected from outpatients of
Okayama University Hospital. The characteristics of these study
patients are summarized in Table 2. The details of patients with
other kidney disease (OKD) except IgAN are listed in Table S4.
Human renal biopsy specimens and spot urine were obtained
after receiving written informed consent from all patients. This
study was conducted in accordance with the guidelines proposed
in the Declaration of Helsinki after approval by the Institutional
Review Board of Okayama University. Glomerular injury and
tubulointerstitial injury were evaluated by Periodic acid-Schiff
(PAS) staining and Masson trichrome staining of sections,
respectively [30,45]. (Detailed methodology is described in
Methods S1.)
Figure 6. Double staining of HAA lectin and IgA in renal biopsy specimens, and the quantitative analysis of staining. Renal biopsy
specimens from patients with minor glomerular abnormalities (MGA) (A, D and G), lupus nephritis (LN) (B, E and H) and IgA nephropathy (IgAN) (C, F
and I) were stained for HAA lectin (red) (A–C), IgA (green) (D–F) and their images were merged (yellow) (G–I). In IgAN patients, the IgA-positive areas
were colocalized with HAA lectin-positive area in the glomeruli. On the other hand, there were IgA-positive areas but no HAA lectin-positive areas in
the glomeruli of LN patients. The relative double positive intensities in the glomeruli of IgAN patients were increased compared to those of LN or
MGA patients (J). The double positive areas in the glomeruli of IgAN patients were increased compared to those with LN or MGA (K). Note that certain
segments of tubules and Bowman’s capsules were also stained with HAA lectin. Each column consists of the means 6 SE. MGA, n=9; LN, n=14; and
IgAN, n=17. **P,0.01. The scale bars represent 100 mm.
doi:10.1371/journal.pone.0033965.g006
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The immunofluorescence analyses were performed as described
previously [30,46,47,48]. The following antibodies were used as
primary antibodies: goat anti-human adiponectin Ab (R&D
systems), mouse anti-SMA Ab (Sigma), rabbit anti-human vWF
Ab (DakoCytomation) and FITC-labeled rabbit anti-human IgA
Ab (DakoCytomation) (direct immunofluorescence). In the 53
patients, adiponectin expression was graded as follows: 0, none or
trace: 1, mild: 2, moderate: 3, severe. The mean score of all
glomeruli in each patient was determined as the adiponectin
staining score. Two independent nephrologists trained according
to the training course provided by the Japanese Renal Pathology
Society scored the adiponectin staining while blinded to the
underlying renal diagnosis. (Detailed methodology is described in
Methods S1.)
Glomerular lectin binding assay
Double staining of HAA lectin and anti-human IgA Ab was
performed to detect degalactosylated IgA1 [4,21]. The unfixed
frozen 4 mm sections of renal biopsy specimens were preincubated
with an avidin/biotin blocking kit (Vector Laboratories), and
stained with biotinylated HAA lectin (10 mg/ml), for 1 h at room
temperature, followed by staining with Alexa-594 conjugated
streptavidin or rabbit anti-human IgA Ab. We examined the
double positive intensities or double positive areas in the glomeruli
by a digital image analysis using the image J software program
(available at http://rsb.info.nih.gpv/ij). The relative intensities in
theglomeruliofIgANorLNpatientstothoseofMGApatientswere
calculated. (Detailed methodology is described in Methods S1.)
Statistical analysis
Data, shown as the means 6 SE, were analyzed by the
Wilcoxon test using the JMP for windows software package version
8.0.2 (SAS Institute Inc., Cawy, NC, USA). P values.0.05 were
considered to be statistically significant.
Supporting Information
Figure S1 The lectin binding assay for native IgA or
deSial/deGal IgA1 to Helix aspersa (HAA) (A) or
Sambucus nigra agglutinin (SNA) (B). The efficacy of the
enzymatic treatment with neuraminidase/beta3-galactosidase was
confirmed by specific lectin-binding assay to HAA (A) and SNA
(B), which specifically bind the terminal GalNAc and sialic acid in
the hinge region of IgA1, respectively (A, B). The left two lanes of
duplicate wells correspond to serial dilutions of native IgA binding
to HAA (A) or SNA (B) lectin. The inset graphs show the dose
response curve of the IgA concentration and HAA (A) or SNA (B)
to IgA binding levels. The deSial/deGal IgA1 reacted more
strongly to HAA lectin than native IgA in duplicate wells of two
lanes (A, top), while it reacted more weakly to SNA lectin than
native IgA (B, top). Each IgA level was adjusted to 1 mg/ml.
(TIF)
Figure 7. The urinary HAA/SNA binding ratio in patients with IgAN and other kidney diseases. The HAA/SNA ratios were determined by
the HAA or SNA lectin binding assays using anti-IgA antibody-coated plates. The HAA/SNA ratio was higher in IgAN patients compared to patients
with other kidney diseases (OKD) (P,0.05) (A). The level of HAA binding corrected for the urinary creatinine concentration was also higher in IgAN
patients compared to patients with OKD (P,0.05) (B). Each column consists of the means 6 SE. OKD, n=142; IgAN, n=78*P,0.05.
doi:10.1371/journal.pone.0033965.g007
Table 2. The profiles of the patients included in the analysis
of urine samples.
OKD
(n=142)
IgAN
(n=78)
Mean age (years) 56.961.4 45.361.8
a
Gender (male/female) 78/75 42/36
eGFR (ml/min/1.73 m
2)5 2 . 2 62.5 66.863.1
a
Serum IgA (mg/dl) 265.4610.5 285.7613.0
C3 (mg/dl) 101.462.3 101.162.5
IgA/C3 2.860.1 3.060.0
Urinary protein (g/day) 0.760.1 0.660.1
Urinary occult blood (grade) 0.460.0 1.060.1
a
Urinary RBC (/hpf) 2.960.4 10.661.7
a
Urinary IgA (mg/ml) 50.6611.1 58.6628.8
Urinary creatinine (mg/dl) 88.665.0 108.768.3
b
HA binding (unit) 6.360.5 12.261.4
SNA binding (unit) 86.267.0 105.6612.0
OKD, other kidney disease; IgAN, IgA nephropathy; eGFR, estimated glomerular
filtration rate; RBC, red blood cell; HAA, Helix aspersa; SNA, Sambucus nigra
agglutinin.
a: P,0.01,
b: P,0.05.
doi:10.1371/journal.pone.0033965.t002
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IgA or deSial/deGal IgA1 in human mesangial cells
(HMCs) (A to C). Neither native nor deSial/deGal IgA1
induced leptin, another adipokine, in the supernatants or cell
lysates of HMCs. HMCs were cultured with different concentra-
tions of native or deSial/deGal IgA1 (0, 6, 12.5, 25 and 50 mg/ml)
for 48 h. For the time course study, HMCs were cultured with
25 mg/ml of native or deSial/deGal IgA1 for 0, 1, 6, 24 or 48 h.
The concentrations of leptin were expressed as the means 6 SE.
Open diamonds, native IgA; closed circles, deSial/deGal IgA1.
(TIF)
Figure S3 The expression of adiponectin, aSMA and
vWF in vessels of renal biopsy specimens. The immuno-
fluorescent staining of renal biopsy specimens from patients with
minor glomerular abnormalities (MGA; A and D), lupus nephritis
(LN; B and E) and IgA nephropathy (IgAN; C and F). Merged
images of aSMA (red) (a marker of vascular smooth muscle cells)
and adiponectin (green) are shown in the upper panels (A to C).
Merged images of vWF (red) (a marker of vascular endothelial
cells) and adiponectin (green) are shown in the lower panels (D to
F). Some adiponectin-positive areas were also positive for aSMA
and vWF. No significant differences in the intensity and pattern of
staining were observed among the three groups of patients. The
scale bars represent 100 mm.
(TIF)
Figure S4 ELISA of the total (A, C, D) and HMW (B, E)
adiponectin and leptin (F to H) after stimulation with
native or deSial/deGal IgA1 in human glomerular
endothelial cells (hGECs). In hGECs, native IgA upregulated
the total (A) and high molecular weight (HMW) (B) adiponectin
release to the supernatants in a dose- (A, B) and time-dependent
manner (C). Native IgA also increased the total and HMW
adiponectin concentration in cell lysates in a dose-dependent
manner (D, E). Neither native nor deSial/deGal IgA1 induced
leptin, another adipokine, in the supernatants or cell lysates of
hGECs (F to H). The hGECs were cultured with different
concentrations of native or deSial/deGal IgA1 (0, 6, 12.5, 25 or
50 mg/ml) for 48 h. For the time course study, the HMCs were
cultured with 25 mg/ml of native or deSial/deGal IgA1 for 0, 1, 6,
24 or 48 h. The concentrations of adiponectin were expressed as
the means 6 SE. Open diamonds, native IgA; closed circles,
deSial/deGal IgA1. *P=0.05 vs. medium control; #P=0.01,
native IgA vs. deSial/deGal IgA1.
(TIF)
Table S1 Upregulated proteins in the supernatants of
HMCs after stimulation with deSial/deGal IgA1.
(DOC)
Table S2 Proteins downregulated in the supernatants of
HMCs after stimulation with deSial/deGal IgA1.
(DOC)
Table S3 The primers used for RT-PCR.
(DOC)
Table S4 The details of the other kidney diseases except
IgAN present in patients who provided urine samples for
analysis.
(DOC)
Methods S1 Generation of deSial/deGal IgA1.
(DOC)
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